By conjugating the cetuximab antibody to the modified starch and using its ability to actively target overexpressed EGFR HNSCC tumor cells, we aim to achieve the targeting of our delivery system for precise therapeutic outcomes. This evidence concerns the gene EGFR and neoplasm.